Nintedanib Esylate

CAS 656247-17-5 19 current recordsSmall Molecule

Who holds supplier records for Nintedanib Esylate? 19 organisations hold a current record for Nintedanib Esylate: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (8), China (5), Finland (1), Taiwan (1) and 3 other countries (3); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 13 Nov 2026. How we read these records

Cite as: PharmaTek, “Nintedanib Esylate: DMF and CEP holder records”, record as of 13 Nov 2026, pharmatek.co.uk/directory/api/nintedanib-esylate

Reading the evidence

  • 19 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 12 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (19)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Nintedanib Esylate. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Nintedanib Esylate sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Nintedanib Esylate is a tyrosine kinase inhibitor used in the treatment of idiopathic pulmonary fibrosis and certain types of non-small cell lung cancer. It inhibits multiple receptor pathways, leading to reduced tumor angiogenesis and fibrosis.

Chemical identity

IUPAC name
ethanesulfonic acid;methyl (3Z)-3-[[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]anilino]-phenylmethylidene]-2-oxo-1H-indole-6-carboxylate
Canonical SMILES
CCS(=O)(=O)O.CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N/C(=C\3/C4=C(C=C(C=C4)C(=O)OC)NC3=O)/C5=CC=CC=C5
InChIKey
MMMVNAGRWOJNMW-FJBFXRHMSA-N
Synonyms
Ofev API, nintedanib esilate, nintedanib ethanesulfonate, ofev

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Kinase Inhibitor
Mechanism of action
Protein Kinase Inhibitors

Therapeutic areas

PulmonologyOncology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Nintedanib Esylate?

19 organisations hold an active US FDA Type II Drug Master File or a CEP for Nintedanib Esylate: CHONGQING HUAPONT SHENGCHEM PHARMACEUTICAL CO LTD (China), ALIVUS LIFE SCIENCES LTD (India), BDR LIFESCIENCES PRIVATE LIMITED (India), Biocon Limited (India), CHEMO IBERICA SA, Cipla Limited (India), FERMION OY (Finland) and Formosa Laboratories, Inc. (Taiwan), and 11 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Nintedanib Esylate Drug Master Files are active?

CHONGQING HUAPONT SHENGCHEM PHARMACEUTICAL CO LTD (DMF 44101, 40620), ALIVUS LIFE SCIENCES LTD (DMF 32152), BDR LIFESCIENCES PRIVATE LIMITED (DMF 40208), Biocon Limited (DMF 41354), CHEMO IBERICA SA (DMF 39158), Cipla Limited (DMF 32504), FERMION OY (DMF 33361) and Formosa Laboratories, Inc. (DMF 32643) and 11 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

How do I qualify a Nintedanib Esylate supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Nintedanib Esylate?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.